DalsnaFinance › IPOs › Evommune Inc › IPO
Evommune, Inc. completed its initial public offering on NYSE on November 6, 2025, pricing at $16.00 a share.
| Ticker | EVMN |
|---|---|
| Exchange | NYSE |
| Status | Completed |
| Listing date | November 6, 2025 |
| Offering price | $16.00 |
| Shares offered | 9,375,000 |
| Total raised | $150M |
Evommune, Inc. sold 9,375,000 shares at $16.00 each on NYSE. Multiplied out, that is $150 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $150 million total recorded for the deal.
Measured by money raised, Evommune, Inc. was tied for the 268th largest (level with 33 other deals) of 473 completed IPOs with a recorded deal size that this site tracks since October 5, 2024. The median deal in the same window raised $200 million.
Among the 126 listings on NYSE alone, it is tied for the 70th largest (level with 4 other listings).
November 2025 saw 20 completed IPOs in the site's data; by amount raised, Evommune, Inc. was tied for the 10th largest (level with 4 other deals) of the 20 deals with a recorded size.
Its $16.00 offer price was tied for the 109th highest (level with 11 other listings) of the 479 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Evommune, Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for Evommune, Inc.. This page is general information, not investment advice.